Hormone signalling and non-coding RNAs in cancer - Cecilia Williams
Our research focuses on understanding key molecular mechanisms in cancer. Each cancer is unique and there is an urgent need for precision medicine, diagnostic tools and novel treatment approaches to reduce cancer mortality. We use a combination of large-scale omics together with focused mechanistic experiments and in vivo studies.
Our goal is to understand critical cancer pathways so that we can suggest better cancer treatments and preventive approaches, as well as biomarkers, to be developed for clinical use.
Non-coding RNA molecules are RNAs that do not encode for proteins. The family includes microRNAs which regulate translation of target mRNAs and long non-coding RNAs (lncRNAs) which can have active functions such as 3D-RNA molecules. Both types can function as biomarkers or therapeutic targets. We study how non-coding RNAs are impacted by cell differentiation, hormone signalling and cancer, and their corresponding functions.
Oestrogene signalling and sex differences in cancer
Some cancers (such as colorectal and liver) are more common in men, and others (breast and thyroid) are more common in women. We explore how the hormone oestrogen influences this and, for example, increases the growth of breast cancer while protecting against colorectal cancer.
The effect of oestrogen is mediated by three oestrogen receptors: ERα, ERβ and GPER1. These are expressed to various extent in different tissues in both women and men. ERα and ERβ are ligand-activated nuclear receptors and are excellent therapeutic targets. GPER1 is a G protein-coupled transmembrane receptor with promising therapeutic potential. Using technologies like RNA-Seq, ChIP-Seq, microbiota analysis, and proteomics, along with cell models, tissue-specific knockouts and clinical samples, we explore how these three receptors, and their ligands such as dietary oestrogens or endocrine disruptors, impact cancer. We are interested in understanding how this contributes to sex differences in cancer incidences and outcomes, as well as the intricate connection with diet/obesity, inflammation and carcinogenesis. Our goal is to contribute to better biomarkers, therapeutics and preventive approaches.
Sexual dimorphism in the incidence of human cancers.
Zheng D, Trynda J, Williams C, Vold JA, Nguyen JH, Harnois DM, et al
BMC Cancer 2019 Jul;19(1):684
A miR-206 regulated gene landscape enhances mammary epithelial differentiation.
Wang J, Aydoğdu E, Mukhopadhyay S, Helguero LA, Williams C
J. Cell. Physiol. 2019 Dec;234(12):22220-22233
Antibody Validation Strategy for Nuclear Receptors.
Katona B, Ibrahim A, Sundberg M, Williams C
Methods Mol. Biol. 2019 ;1966():79-99
Colitis-induced colorectal cancer and intestinal epithelial estrogen receptor beta impact gut microbiota diversity.
Ibrahim A, Hugerth LW, Hases L, Saxena A, Seifert M, Thomas Q, et al
Int. J. Cancer 2019 06;144(12):3086-3098
Regulation of sex hormone receptors in sexual dimorphism of human cancers.
Zheng D, Williams C, Vold JA, Nguyen JH, Harnois DM, Bagaria SP, et al
Cancer Lett. 2018 12;438():24-31
A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.
Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, et al
Cancer Cell 2018 04;33(4):690-705.e9
Insufficient antibody validation challenges oestrogen receptor beta research.
Andersson S, Sundberg M, Pristovsek N, Ibrahim A, Jonsson P, Katona B, et al
Nat Commun 2017 06;8():15840
- Pan-Gynecologic Cancers Analysis Working Group, The Cancer Genome Atlas
- VR Research environment Interdisciplinary research (QuantumSense 2018-2025)
- American Association for Cancer Research (AACR)
- Career Development Award (VINNOVA/ Marie-Curie Actions GROWTH 291795, Cecilia Williams, 2014-2018)
- National Cancer Institute / NIH USA (R01 CA172437, 2013-2019)